Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

• Sponsor: Aegerion Pharmaceuticals, Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00359281
• Collaborator: (none)
• Enrollment: 125
• Location: 1
• Duration (Months): 20
• Patients Per Site Per Month: 6.2

Study Details

Study Description

Brief Summary

This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10 or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10) or fifteen (15) subjects.

Safety, pharmacokinetic and pharmacodynamic assessments will be performed.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: atorvastatin; Drug: simvastatin; Drug: ezetimibe; Drug: fenofibrate; Drug: dextromethorphan; Drug: Extended Release Niacin	Phase 2

Detailed Description

Objectives:

Primary: To evaluate the effects of low and high doses of AEGR-733 on the pharmacokinetics of 6 FDA-approved medications that are likely to be used in combination with AEGR-733 as assessed by:

• Pharmacokinetic parameters: Cmax, Tmax, T1/2, and AUC (area under the curve).

Secondary: To evaluate the safety of AEGR-733 in combination with other lipid lowering agents in healthy subject as assessed by:

• Changes in associated liver enzymes AST, ALT and, Alkaline Phosphatase, & Total Bilirubin.

• Changes in all reported adverse events.

• To evaluate the effects of AEGR-733 in combination with other lipid lowering agents on the following lipids and lipoproteins: TC, LDL-C, VLDL, TG, HDL-C, ApoB and ApoAI.

4.0 STUDY DESIGN AND RATIONALE

4.1 STUDY DESIGN This is a single-center, phase II, clinical trial consisting of a eight (8) day open-label phase to assess the pharmacokinetic drug interactions of AEGR-733 on 6 probe drugs in healthy volunteers, followed by a one week safety visit. 105 subjects will be enrolled into this fixed-sequenced research study. Eligible subjects based on the screening visit will come to the GCRC for an inpatient visit (25-36 hr depending on if they come in evening before study day 1 or morning of). On the morning of study day 1, subjects will be assigned to one of 6 probe drugs(A-H below) and will take one dose of this medication. Timed blood samples will be drawn just before the administration of the probe drug and during the following times after drug administration (1,2,3,4,5,6,8,10,12,18, and 24 hrs). Prior to discharge after the 24 h blood sample, subjects will take an oral dose of AEGR-733 at 10 mg or 60 mg. Subjects will be given a 5 day supply of AEGR-733 at 10 mg or 60 mg to be taken once daily in the morning for the next 5 days (through day 7). On study day 8, subjects will take a final dose of AEGR-733 at 10 mg or 60 mg (total doses= 7) simultaneously with the same probe drug they took on day 1. Timed blood samples will be drawn just before the administration of the probe drug and AEGR-733 as well as 1,2,3,4,5,6,8,10,12,18, and 24 hours after study drug administration. After the 24 hour blood sample, subjects will be discharged. 15 subjects who participate in this study will receive dextromethorphan as the probe drug, which requires urine collection for 8 hours post dose. Blood for pharmacokinetic samples will not be collected on these subjects. Subjects receiving dextromethorphan may leave after the 8 hour urine collection at visits 2 and 3 (referred to as the inpatient visits). All subjects will come back 1 week later for a final visit to check safety lab parameters including liver transaminases and total bilirubin. Subjects will be instructed to abstain from drinking any alcoholic beverages once screened until study completion. Subjects who are not willing to comply with these requests will not be enrolled.

The FDA-approved lipid-lowering therapies will include:

1. Atorvastatin, 20 mg (n=15)and AEGR-733 10 mg B) Ezetimibe, 10 mg (n=10)and AEGR-733 10 mg
2. Simvastatin, 20 mg (n=15)and AEGR-733 10 mg D) Rosuvastatin, 20 mg (n=10)and AEGR-733 10 mg E) Micronized fenofibrate, 145 mg (n=10)and AEGR-733 10 mg F) Atorvastatin, 20 mg (n=15) and AEGR-733 60 mg G) Rosuvastatin, 20 mg (n=15) and AEGR-733 60 mg H) Dextromethorphan, 30 mg (n=15) and AEGR-733 60 mg I) Extended Release Niacin, 1000 mg (n=20) and AEGR-733 10 mg

Study Design

• Study Type: Interventional
• Actual Enrollment: 125 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers
• Study Start Date: Mar 1, 2006
• Actual Primary Completion Date: Nov 1, 2007
• Actual Study Completion Date: Nov 1, 2007

Outcome Measures

Primary Outcome Measures

1. Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg) [0 to 24 hour]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg)

2. AUC0-t Simvastatin [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin

3. AUC0-t Simvastatin Acid [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid

4. AUC0-t Total Ezetimibe [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe

5. AUC0-t Rosuvastatin (Lomitapide 10 mg) [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg)

6. AUC0-t Fenofibric Acid [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid

7. AUC0-t Atorvastatin Acid (Lomitapide 60 mg) [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg)

8. AUC0-t Rosuvastatin (Lomitapide 60 mg) [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg)

9. AUC0-t Nicotinic Acid [0 to 24 hours]

   Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid

10. AUC0-t Nicotinuric Acid [0 to 24 hours]

    Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid

Secondary Outcome Measures

1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) [Baseline to Day 8]

   Percent change from Baseline in LDL-C

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Males and non-pregnant/non-lactating female subjects between the ages of 18 and 70 who are in good overall health.

To be eligible for enrollment in this study, patients must meet all of the following criteria:

1. Men and women between the ages of 18 and 70

2. Women of child-bearing potential, that is, women not surgically sterilized and between menarche and 1 year post menopause, must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of non-medication birth control (for example, a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices]; partner with vasectomy; or abstinence) during the study and for one month following the last dose of study drug.

3. Subjects must be in good overall health

4. Subjects must be able to comprehend and willing to provide a signed IRB approved Informed Consent Form.

5. Subjects must be willing to comply with all study-related procedures.

Exclusion Criteria:

1. Known atherosclerotic cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease

2. History of diabetes mellitus or fasting glucose > 126 mg/dL at the screening visit.

3. History of a non-skin malignancy within the previous 5 years

4. Renal insufficiency as defined by creatinine > 1.3 mg/dl

5. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition

6. History of hypertension

7. Known coagulopathy and /or elevated PT/PTT >1.5 x ULN

8. Oral history of HIV positive

9. Patients who have undergone any organ transplant

10. Known active fibrotic or cirrhotic disease; ALT or AST > 1.5x ULN

11. Any major surgery within the previous 3 months

12. Individuals who currently use tobacco products or have done so in the previous 30 days

13. History of drug abuse (< 3 years)

14. Regular use of alcoholic beverages (> 7 drinks/day)

15. Subjects who do not agree to abstain from consuming alcoholic beverages during the entire study duration.

16. Body mass index (BMI) > 30 kg/m2 or < 18.5 kg/m2

17. Participation in an investigational drug study within 6 weeks prior to the screening visit

18. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study will be excluded.

19. Currently taking any prescription, including oral contraceptives, or OTC medication regularly that cannot be stopped for at least 30 days prior to enrollment until completion of the study

20. Regular consumers of grapefruit juice, or have taken any medications known to be metabolized by CYP 3A4 within 4 weeks prior to the screening visit (ie. SSRIs, anti-fungals, anti-biotics, etc)

21. History of myalgia with a statin or unknown hypersensitivity to any statin, zetia, AEGR-733, or fenofibrate.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104

Sponsors and Collaborators

• Aegerion Pharmaceuticals, Inc.

Investigators

• Principal Investigator: Marina Cuchel, MD, PhD, University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Aegerion Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT00359281
• Other Study ID Numbers: AEGR-733-002; Aegerion 002 PK study
• First Posted: Aug 2, 2006
• Last Update Posted: Feb 23, 2018
• Last Verified: Feb 1, 2018

• Keywords provided by Aegerion Pharmaceuticals, Inc.: healthy volunteers
• Additional relevant MeSH terms: Niacin; Dextromethorphan; Atorvastatin; Simvastatin; Ezetimibe; Fenofibrate

Study Results

Participant Flow

Recruitment Details	The study was performed from 19 May 2006 to 20 November 2007 at 1 medical clinic within the United States.

Arm/Group Title	Atorvastatin 20 mg + Lomitapide 10 mg	Simvastatin 20 mg + Lomitapide 10 mg	Ezetimibe 10 mg + Lomitapide 10 mg	Rosuvastatin 20 mg + Lomitapide 10 mg	Fenofibrate 145 mg + Lomitapide 10 mg	Atorvastatin 20 mg + Lomitapide 60 mg	Rosuvastatin 20 mg + Lomitapide 60 mg	Dextrometh-rophan 30 mg + Lomitapide 60 mg	ER Niacin 1000 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg	One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg	One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg	One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg	One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg	One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg	One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg
Period Title: Overall Study
STARTED	16	15	10	10	10	15	18	15	20
COMPLETED	15	15	10	10	10	15	16	15	20
NOT COMPLETED	1	0	0	0	0	0	2	0	0

Baseline Characteristics

Arm/Group Title	Atorvastatin 20 mg + Lomitapide 10 mg	Simvastatin 20 mg + Lomitapide 10 mg	Ezetimibe 10 mg + Lomitapide 10 mg	Rosuvastatin 20 mg + Lomitapide 10 mg	Fenofibrate 145 mg + Lomitapide 10 mg	Atorvastatin 20 mg + Lomitapide 60 mg	Rosuvastatin 20 mg + Lomitapide 60 mg	Dextrometh-rophan 30 mg + Lomitapide 60 mg	ER Niacin 1000 mg + Lomitapide 10 mg	Total
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg	One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg	One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg	One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg	One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg	One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg	One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg	Total of all reporting groups
Overall Participants	16	15	10	10	10	15	18	15	20	129
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	26 (7)	29 (12)	29 (9)	31 (13)	24 (3)	27 (8)	31 (13)	27 (9)	29 (11)	28 (10)
Sex: Female, Male (Count of Participants)
Female	7 43.8%	10 66.7%	3 30%	2 20%	2 20%	5 33.3%	9 50%	6 40%	9 45%	53 41.1%
Male	9 56.3%	5 33.3%	7 70%	8 80%	8 80%	10 66.7%	9 50%	9 60%	11 55%	76 58.9%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	3 18.8%	2 13.3%	0 0%	0 0%	1 10%	3 20%	1 5.6%	3 20%	2 10%	15 11.6%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	2 12.5%	2 13.3%	1 10%	4 40%	2 20%	1 6.7%	5 27.8%	2 13.3%	4 20%	23 17.8%
White	11 68.8%	11 73.3%	8 80%	5 50%	7 70%	6 40%	11 61.1%	10 66.7%	13 65%	82 63.6%
More than one race	0 0%	0 0%	1 10%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 0.8%
Unknown or Not Reported	0 0%	0 0%	0 0%	1 10%	0 0%	5 33.3%	1 5.6%	0 0%	1 5%	8 6.2%
Region of Enrollment (participants) [Number]
United States	16 100%	15 100%	10 100%	10 100%	10 100%	15 100%	18 100%	15 100%	20 100%	129 100%

Outcome Measures

1. Primary Outcome

Title	Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg)
Time Frame	0 to 24 hour

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Atorvastatin 20 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg
Measure Participants	15
Geometric Mean (90% Confidence Interval) [Ratio]	110.97

2. Secondary Outcome

Title	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Description	Percent change from Baseline in LDL-C
Time Frame	Baseline to Day 8

Outcome Measure Data

Analysis Population Description

Intention To Treat

Arm/Group Title	Atorvastatin 20 mg + Lomitapide 10 mg	Simvastatin 20 mg + Lomitapide 10 mg	Ezetimibe 10 mg + Lomitapide 10 mg	Rosuvastatin 20 mg + Lomitapide 10 mg	Fenofibrate 145 mg + Lomitapide 10 mg	Atorvastatin 20 mg + Lomitapide 60 mg	Rosuvastatin 20 mg + Lomitapide 60 mg	Dextrometh-rophan 30 mg + Lomitapide 60 mg	ER Niacin 1000 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg	One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg	One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg	One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg	One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg	One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg	One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg	One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg
Measure Participants	16	15	10	10	10	15	18	15	20
Mean (Standard Deviation) [Percent Change]	-30.99 (14.47)	-26.43 (17.77)	-28.36 (12.53)	-41.74 (10.37)	-20.12 (25.56)	-66.02 (15.18)	-63.20 (18.59)	-46.07 (33.12)	-20.89 (15.17)

3. Primary Outcome

Title	AUC0-t Simvastatin
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Simvastatin 20 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg
Measure Participants	15
Geometric Mean (90% Confidence Interval) [Ratio]	162.25

4. Primary Outcome

Title	AUC0-t Simvastatin Acid
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Simvastatin 20 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg
Measure Participants	15
Geometric Mean (90% Confidence Interval) [Ratio]	138.76

5. Primary Outcome

Title	AUC0-t Total Ezetimibe
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Ezetimibe 10 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg
Measure Participants	10
Geometric Mean (90% Confidence Interval) [Ratio]	105.71

6. Primary Outcome

Title	AUC0-t Rosuvastatin (Lomitapide 10 mg)
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg)
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Rosuvastatin 20 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg
Measure Participants	10
Geometric Mean (90% Confidence Interval) [Ratio]	102.05

7. Primary Outcome

Title	AUC0-t Fenofibric Acid
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Fenofibrate 145 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg
Measure Participants	10
Geometric Mean (90% Confidence Interval) [Ratio]	89.62

8. Primary Outcome

Title	AUC0-t Atorvastatin Acid (Lomitapide 60 mg)
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg)
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Atorvastatin 20 mg + Lomitapide 60 mg
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg
Measure Participants	15
Geometric Mean (90% Confidence Interval) [Ratio]	152.32

9. Primary Outcome

Title	AUC0-t Rosuvastatin (Lomitapide 60 mg)
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg)
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	Rosuvastatin 20 mg + Lomitapide 60 mg
Arm/Group Description	One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg
Measure Participants	15
Geometric Mean (90% Confidence Interval) [Ratio]	132.21

10. Primary Outcome

Title	AUC0-t Nicotinic Acid
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	ER Niacin 1000 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg
Measure Participants	20
Geometric Mean (90% Confidence Interval) [Ratio]	110.22

11. Primary Outcome

Title	AUC0-t Nicotinuric Acid
Description	Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid
Time Frame	0 to 24 hours

Outcome Measure Data

Analysis Population Description

Pharmacokinetic

Arm/Group Title	ER Niacin 1000 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg
Measure Participants	20
Geometric Mean (90% Confidence Interval) [Ratio]	79.15

Adverse Events

Time Frame	From the first dose of study drug (Day 1) to 14 days after the first dose (Day 15)
Arm/Group Title	Atorvastatin 20 mg + Lomitapide 10 mg		Simvastatin 20 mg + Lomitapide 10 mg		Ezetimibe 10 mg + Lomitapide 10 mg		Rosuvastatin 20 mg + Lomitapide 10 mg		Fenofibrate 145 mg + Lomitapide 10 mg		Atorvastatin 20 mg + Lomitapide 60 mg		Rosuvastatin 20 mg + Lomitapide 60 mg		Dextrometh-rophan 30 mg + Lomitapide 60 mg		ER Niacin 1000 mg + Lomitapide 10 mg
Arm/Group Description	One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg		One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg		One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg		One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg		One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg		One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg		One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg		One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg		One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg
All Cause Mortality
	Atorvastatin 20 mg + Lomitapide 10 mg		Simvastatin 20 mg + Lomitapide 10 mg		Ezetimibe 10 mg + Lomitapide 10 mg		Rosuvastatin 20 mg + Lomitapide 10 mg		Fenofibrate 145 mg + Lomitapide 10 mg		Atorvastatin 20 mg + Lomitapide 60 mg		Rosuvastatin 20 mg + Lomitapide 60 mg		Dextrometh-rophan 30 mg + Lomitapide 60 mg		ER Niacin 1000 mg + Lomitapide 10 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	Atorvastatin 20 mg + Lomitapide 10 mg		Simvastatin 20 mg + Lomitapide 10 mg		Ezetimibe 10 mg + Lomitapide 10 mg		Rosuvastatin 20 mg + Lomitapide 10 mg		Fenofibrate 145 mg + Lomitapide 10 mg		Atorvastatin 20 mg + Lomitapide 60 mg		Rosuvastatin 20 mg + Lomitapide 60 mg		Dextrometh-rophan 30 mg + Lomitapide 60 mg		ER Niacin 1000 mg + Lomitapide 10 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Other (Not Including Serious) Adverse Events
	Atorvastatin 20 mg + Lomitapide 10 mg		Simvastatin 20 mg + Lomitapide 10 mg		Ezetimibe 10 mg + Lomitapide 10 mg		Rosuvastatin 20 mg + Lomitapide 10 mg		Fenofibrate 145 mg + Lomitapide 10 mg		Atorvastatin 20 mg + Lomitapide 60 mg		Rosuvastatin 20 mg + Lomitapide 60 mg		Dextrometh-rophan 30 mg + Lomitapide 60 mg		ER Niacin 1000 mg + Lomitapide 10 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/16 (50%)		8/15 (53.3%)		6/10 (60%)		3/10 (30%)		6/10 (60%)		12/15 (80%)		15/18 (83.3%)		11/15 (73.3%)		18/20 (90%)
Cardiac disorders
Palpitations	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		2/20 (10%)
Gastrointestinal disorders
Diarrhoea	3/16 (18.8%)		4/15 (26.7%)		1/10 (10%)		0/10 (0%)		3/10 (30%)		7/15 (46.7%)		9/18 (50%)		4/15 (26.7%)		2/20 (10%)
Nausea	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		2/10 (20%)		2/15 (13.3%)		3/18 (16.7%)		3/15 (20%)		2/20 (10%)
Abdominal discomfort	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		5/15 (33.3%)		2/18 (11.1%)		5/15 (33.3%)		1/20 (5%)
Flatulence	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		3/15 (20%)		2/18 (11.1%)		1/15 (6.7%)		2/20 (10%)
Abnormal faeces	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		2/15 (13.3%)		0/18 (0%)		1/15 (6.7%)		3/20 (15%)
Abdominal pain upper	0/16 (0%)		2/15 (13.3%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		0/15 (0%)		4/20 (20%)
Abdominal distension	0/16 (0%)		0/15 (0%)		3/10 (30%)		1/10 (10%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		1/15 (6.7%)		0/20 (0%)
Vomiting	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/15 (6.7%)		2/18 (11.1%)		0/15 (0%)		1/20 (5%)
Constipation	0/16 (0%)		1/15 (6.7%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		1/15 (6.7%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Dyspepsia	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Eructation	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Faeces discoloured	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Gastrooesophageal reflux disease	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Faeces hard	0/16 (0%)		0/15 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Abdominal pain	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		0/15 (0%)		0/20 (0%)
Gastric dilatation	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		0/15 (0%)		0/20 (0%)
Haemorrhoids	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		0/15 (0%)		0/20 (0%)
General disorders
Fatigue	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		6/15 (40%)		0/20 (0%)
Chills	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		3/20 (15%)
Pyrexia	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		2/15 (13.3%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Infusion site haematoma	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/15 (6.7%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Infusion site pain	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		0/15 (0%)		0/20 (0%)
Malaise	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		1/15 (6.7%)		0/20 (0%)
Injury, poisoning and procedural complications
Laceration	0/16 (0%)		0/15 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia	0/16 (0%)		0/15 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		1/15 (6.7%)		0/20 (0%)
Back pain	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		1/18 (5.6%)		1/15 (6.7%)		0/20 (0%)
Musculoskeletal chest pain	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Nervous system disorders
Headache	0/16 (0%)		2/15 (13.3%)		1/10 (10%)		2/10 (20%)		0/10 (0%)		1/15 (6.7%)		1/18 (5.6%)		0/15 (0%)		3/20 (15%)
Paraesthesia	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		7/20 (35%)
Dizziness	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		0/15 (0%)		1/18 (5.6%)		2/15 (13.3%)		2/20 (10%)
Dysgeusia	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Renal and urinary disorders
Chromaturia	1/16 (6.3%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		3/20 (15%)
Skin and subcutaneous tissue disorders
Pruritus	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		7/20 (35%)
Rash	0/16 (0%)		1/15 (6.7%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		0/20 (0%)
Vascular disorders
Flushing	0/16 (0%)		0/15 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/15 (0%)		0/18 (0%)		0/15 (0%)		12/20 (60%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.